These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 25729046)

  • 1. Drs. Moon and Min reply.
    Moon SJ; Min JK
    J Rheumatol; 2015 Mar; 42(3):553. PubMed ID: 25729046
    [No Abstract]   [Full Text] [Related]  

  • 2. Interleukin-34: a potential diagnostic and therapeutic target for rheumatoid arthritis.
    He W; Xu XD; Dong YM; Wu H
    J Rheumatol; 2015 Mar; 42(3):553. PubMed ID: 25729045
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased levels of interleukin 34 in serum and synovial fluid are associated with rheumatoid factor and anticyclic citrullinated peptide antibody titers in patients with rheumatoid arthritis.
    Moon SJ; Hong YS; Ju JH; Kwok SK; Park SH; Min JK
    J Rheumatol; 2013 Nov; 40(11):1842-9. PubMed ID: 23996288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Authors' reply.
    Sun X; Li Z
    Scand J Rheumatol; 2014; 43(2):176. PubMed ID: 24588514
    [No Abstract]   [Full Text] [Related]  

  • 5. Elevated serum and synovial fluid TNF-like ligand 1A (TL1A) is associated with autoantibody production in patients with rheumatoid arthritis: comments on the article by Sun et al.
    Cao L; Xu T; Huang C; Li J
    Scand J Rheumatol; 2014; 43(2):175. PubMed ID: 24559200
    [No Abstract]   [Full Text] [Related]  

  • 6. Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis.
    Caspi D; Anouk M; Golan I; Paran D; Kaufman I; Wigler I; Levartovsky D; Litinsky I; Elkayam O
    Arthritis Rheum; 2006 Feb; 55(1):53-6. PubMed ID: 16463412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reply to Xie et al. about the article "Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis".
    Talabot-Ayer D; Gabay C; Palmer G
    Joint Bone Spine; 2013 Jan; 80(1):117-8. PubMed ID: 23182161
    [No Abstract]   [Full Text] [Related]  

  • 8. Likelihood ratios as a function of antibody concentration for anti-cyclic citrullinated peptide antibodies and rheumatoid factor.
    Bossuyt X; Coenen D; Fieuws S; Verschueren P; Westhovens R; Blanckaert N
    Ann Rheum Dis; 2009 Feb; 68(2):287-9. PubMed ID: 19139208
    [No Abstract]   [Full Text] [Related]  

  • 9. Rheumatoid factor and anti-CCP autoantibodies in rheumatoid arthritis: a review.
    Lee AN; Beck CE; Hall M
    Clin Lab Sci; 2008; 21(1):15-8. PubMed ID: 18335856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokines in synovial fluid in rheumatoid arthritis.
    Smith MD
    J Rheumatol; 1989 May; 16(5):706-7. PubMed ID: 2754675
    [No Abstract]   [Full Text] [Related]  

  • 11. Dimethylated L-arginine analogues versus autoantibodies in early rheumatoid arthritis.
    Korkosz M; Sulicka J; Surdacki A
    Scand J Rheumatol; 2012 Feb; 41(1):82-3. PubMed ID: 22283801
    [No Abstract]   [Full Text] [Related]  

  • 12. [Rheumatoid arthritis: progress in diagnosis and treatment. Topics: II. Pathophysiology; 3. Autoantibodies in rheumatoid arthritis].
    Murakami K; Fujii T; Mimori T
    Nihon Naika Gakkai Zasshi; 2012 Oct; 101(10):2844-50. PubMed ID: 23214092
    [No Abstract]   [Full Text] [Related]  

  • 13. Cathepsin S and cathepsin L in serum and synovial fluid in rheumatoid arthritis with and without autoantibodies.
    Weitoft T; Larsson A; Manivel VA; Lysholm J; Knight A; Rönnelid J
    Rheumatology (Oxford); 2015 Oct; 54(10):1923-8. PubMed ID: 26060322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification criteria for rheumatoid arthritis--time to abandon rheumatoid factor?
    Symmons DP
    Rheumatology (Oxford); 2007 May; 46(5):725-6. PubMed ID: 17215261
    [No Abstract]   [Full Text] [Related]  

  • 15. Elevated serum and synovial fluid TNF-like ligand 1A (TL1A) is associated with autoantibody production in patients with rheumatoid arthritis.
    Sun X; Zhao J; Liu R; Jia R; Sun L; Li X; Li Z
    Scand J Rheumatol; 2013; 42(2):97-101. PubMed ID: 23311967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgM-rheumatoid factor and anti-cyclic citrullinated peptide decrease by 50% during intensive treatment in early rheumatoid arthritis.
    van Tuyl LH; Lems WF; Kerstens PJ; Voskuyl AE; Dijkmans BA; Boers M
    Ann Rheum Dis; 2009 Oct; 68(10):1652-3. PubMed ID: 19748920
    [No Abstract]   [Full Text] [Related]  

  • 17. Can we rely on anti-citrulline antibody determination for the diagnosis of early rheumatoid arthritis?
    Bell DA
    J Rheumatol; 2006 Dec; 33(12):2369-71. PubMed ID: 17143974
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of citrullinated cellular fibronectin in synovial fluid from patients with rheumatoid arthritis.
    Kimura E; Kanzaki T; Tahara K; Hayashi H; Hashimoto S; Suzuki A; Yamada R; Yamamoto K; Sawada T
    Mod Rheumatol; 2014 Sep; 24(5):766-9. PubMed ID: 24498912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of rheumatoid factor and anticitrullinated peptide antibodies on bone erosions in rheumatoid arthritis.
    van Steenbergen HW; Ajeganova S; Forslind K; Svensson B; van der Helm-van Mil AH
    Ann Rheum Dis; 2015 Jan; 74(1):e3. PubMed ID: 25288634
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of rheumatoid factor and ACPA on bone erosion in rheumatoid arthritis.
    Hecht C; Schett G; Finzel S
    Ann Rheum Dis; 2015 Jan; 74(1):e4. PubMed ID: 25326218
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.